No Data
No Data
No Data
Nifty Life, Perseus, and others.
<4262> Nifty Life revises its financial estimates, this year's revenue outlook is 4.764 billion yen, increased from 3.946 billion yen. <4593> Extends basic agreement period with Helios Snowbell Pharma. <4882> Perseus PPMX-T003: Polycythemia vera (PV) Phase I trial has been completed. <4888> Stella Pharma will issue large amount of subscription rights (with price adjustment clause) from the 13th, with 541,000 shares. <7066> Piazz IT Works School Business (BOOT CAMP)
Takashimaya revises upwards on February 25, operating profit of 55 billion yen (previously 50 billion yen).
Takashimaya <8233> announced the revision of its financial estimates for the fiscal year ending February 2025. Operating revenue has been revised upward from 497 billion yen to 511.4 billion yen, and operating profit has been revised upward from 50 billion yen to 55 billion yen, reflecting the strong performance of inbound sales at domestic department stores. In addition, for the first quarter of the fiscal year ending February 2025, operating revenue was 120.125 billion yen, a year-on-year increase of 13.8%, and operating profit was 17.295 billion yen, an increase of 56.7% from the previous year. [Positive rating] Intellix <8940> revision.
Nifty Lifestyle: Announcement of revised financial estimates and disclosure of new items.
Nifty Lifestyle: Announcements of individual stocks related to the financial results of unlisted parent companies.
Nifty Lifestyle: Confirmation letter
Nifty Lifestyle: Securities Report - 7th period (April 1, 2023 - March 31, 2024)
No Data